Evidence map›Paper›PMID 36139375›Full record

ArticleCells2022

IgG

Nuno Couto, Julia Elzanowska, Joana Maia, Silvia Batista, Catarina Esteves Pereira, Hans Christian Beck, Ana Sofia Carvalho, Maria Carolina Strano Moraes, Carlos Carvalho, Manuela Oliveira and 2 more

Open access · goldAbstract read
In one paragraph

Article in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Nuno CoutoChampalimaud Physiology and Cancer Programme, Champalimaud Foundation, 1400-038 Lisbon, Portugal.
Julia ElzanowskaChampalimaud Physiology and Cancer Programme, Champalimaud Foundation, 1400-038 Lisbon, Portugal.
Joana MaiaChampalimaud Physiology and Cancer Programme, Champalimaud Foundation, 1400-038 Lisbon, Portugal.
Silvia BatistaChampalimaud Physiology and Cancer Programme, Champalimaud Foundation, 1400-038 Lisbon, Portugal.
Catarina Esteves PereiraChampalimaud Physiology and Cancer Programme, Champalimaud Foundation, 1400-038 Lisbon, Portugal.ORCID 0000-0003-0040-9474
Hans Christian BeckCentre for Clinical Proteomics, Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, Sdr. Boulevard 29, DK-5000 Odense, Denmark.ORCID 0000-0002-7763-3637
Ana Sofia CarvalhoComputational and Experimental Biology Group, iNOVA4Health, NOVA MedicalSchool|Faculdade de Ciências Médicas, NMS|FCM, Universidade Nova de Lisboa, 1150-199 Lisbon, Portugal.ORCID 0000-0003-0657-1907
Maria Carolina Strano MoraesChampalimaud Physiology and Cancer Programme, Champalimaud Foundation, 1400-038 Lisbon, Portugal.
Carlos CarvalhoDigestive Unit, Champalimaud Clinical Centre, Champalimaud Foundation, 1400-038 Lisbon, Portugal.
Manuela OliveiraDepartment of Mathematics and CIMA-Center for Research on Mathematics and Its Applications, University of Évora, 7004-516 Evora, Portugal.
Rune MatthiesenComputational and Experimental Biology Group, iNOVA4Health, NOVA MedicalSchool|Faculdade de Ciências Médicas, NMS|FCM, Universidade Nova de Lisboa, 1150-199 Lisbon, Portugal.ORCID 0000-0002-6353-2616
Bruno Costa-SilvaChampalimaud Physiology and Cancer Programme, Champalimaud Foundation, 1400-038 Lisbon, Portugal.
Champalimaud Foundation · PTUniversidade Nova de Lisboa · PTOdense University Hospital · DKUniversity of Évora · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

(1) Background: Pancreatic ductal adenocarcinoma (PDAC) is expected to be the second-leading cause of cancer deaths by 2030. Imaging techniques are the standard for monitoring the therapy response in PDAC, but these techniques have considerable limits, including delayed disease progression detection and difficulty in distinguishing benign from malignant lesions. Extracellular vesicle (EV) liquid biopsy is an emerging diagnosis modality. Nonetheless, the majority of research for EV-based diagnosis relies on point analyses of EVs at specified times, while longitudinal EV population studies before and during therapeutic interventions remain largely unexplored. (2) Methods: We analyzed plasma EV protein composition at diagnosis and throughout PDAC therapy. (3) Results: We found that IgG is linked with the diagnosis of PDAC and the patient's response to therapy, and that the IgG+ EV population increases with disease progression and reduces with treatment response. Importantly, this covers PDAC patients devoid of the standard PDAC seric marker CA19.9 expression. We also observed that IgG is bound to EVs via the tumor antigen MAGE B1, and that this is independent of the patient's inflammatory condition and IgG seric levels. (4) Conclusions: We here propose that a population analysis of IgG+ EVs in PDAC plasma represents a novel method to supplement the monitoring of the PDAC treatment response.

Indexed as

Carcinoma, Pancreatic DuctalExtracellular VesiclesPancreatic NeoplasmsAntigens, NeoplasmBiomarkers, TumorDisease ProgressionHumansImmunoglobulin GAntigens, NeoplasmBiomarkers, TumorImmunoglobulin Gbiomarkerextracellular vesiclesIgGliquid biopsypancreatic cancer

Identifiers

PMID36139375
PMCPMC9496671
OpenAlexW4296108633

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.